Mode
Text Size
Log in / Sign up
Phase 3 N=80 Randomized Quadruple-blind Treatment

Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation

Reperfusion Injury · Liver Injury

Enrolled (actual)
80
Serious AEs
1.3%
Results posted
Nov 2014
Primary outcome: Primary: Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels) — 83; 86.4 percentage change from baseline

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
inhaled nitric oxide (Drug); nitrogen gas (Drug)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of Alabama at Birmingham
Primary completion
Mar 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels)
83; 86.4
PRIMARY
Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in ALT Levels)
62.3; 62.4
PRIMARY
Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Alkaline Phosphatase Levels)
239.7; 55
PRIMARY
Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Prothrombin Times (PT))
48.9; 25.5
PRIMARY
Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Bilirubin Levels)
6.6; 0.4
PRIMARY
Change in Rate of Liver Function Recovery Post-transplantation (Decrease in Hepatobiliary Complications)
2; 5
PRIMARY
Number of Complications Related to Liver Function Recovery Post-transplantation (Total Complications) at 9 Months Post Surgery
44; 83
SECONDARY
Effect of iNO on Hosptial Length of Stay
9.0; 9.0
SECONDARY
Effect of iNO on SICU Stay
2533; 2518

Summary

This blinded, placebo-controlled study will administer inhaled nitric oxide to patients undergoing liver transplantation. The purpose of the study is to test if inhaled nitric oxide prevents liver injury associated with the restoration of blood flow. The premise of the current study is provided by previous studies which document a protective effect of inhaled nitric oxide in this clinical setting.

Eligibility Criteria

Inclusion Criteria

  • Patients > 19 yr of age scheduled to undergo liver transplantation.

Exclusion Criteria

  • Patients < 19 yr of age
  • Patients undergoing re-transplantation or dual organ transplantation
  • Patients with underlying pulmonary complications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00582010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search